Search Results - "Lam, Clara"

Trends in pediatric thyroid cancer incidence in the United States, 1998‐2013 by Bernier, Marie‐Odile, Withrow, Diana R., Berrington de Gonzalez, Amy, Lam, Clara J. K., Linet, Martha S., Kitahara, Cari M., Shiels, Meredith S.

“…Background Pediatric differentiated thyroid cancer (DTC) rates have increased over time in the United States and worldwide. Improvements in imaging for the…”
Get full text

Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era by Morton, Lindsay M, Dores, Graça M, Schonfeld, Sara J, Linet, Martha S, Sigel, Byron S, Lam, Clara J K, Tucker, Margaret A, Curtis, Rochelle E

“…Therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) is a rare, usually fatal complication of chemotherapy, including certain…”
Get more information

Trends in Pediatric Central Nervous System Tumor Incidence in the United States, 1998-2013 by Withrow, Diana R, de Gonzalez, Amy Berrington, Lam, Clara J K, Warren, Katherine E, Shiels, Meredith S

“…Brain and other central nervous system (CNS) cancers are the leading cause of U.S. pediatric cancer mortality. Incidence trends can provide etiologic insight…”
Get full text

Validation of prostate‐specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries by Adamo, Margaret (Peggy), Boten, Jessica A., Coyle, Linda M., Cronin, Kathleen A., Lam, Clara J. K., Negoita, Serban, Penberthy, Lynne, Stevens, Jennifer L., Ward, Kevin C.

“…BACKGROUND Researchers have used prostate‐specific antigen (PSA) values collected by central cancer registries to evaluate tumors for potential aggressive…”
Get full text

Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study by Advani, Pragati G., Schonfeld, Sara J., Curtis, Rochelle E., Dores, Graça M., Linet, Martha S., Sigel, Byron S., Lam, Clara J. K., Tucker, Margaret A., Chanock, Stephen J., Morton, Lindsay M.

Get full text

Preface to Supplement Titled, SEER-Medicare and Other SEER Linkages: Data Sources, Analytic Methods, and Limitations by Enewold, Lindsey, Lam, Clara J K, Parsons, Helen

Get full text

Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma by Lam, Clara J K, Curtis, Rochelle E, Dores, Graça M, Engels, Eric A, Caporaso, Neil E, Polliack, Aaron, Warren, Joan L, Young, Heather A, Levine, Paul H, Elmi, Angelo F, Fraumeni, Jr, Joseph F, Tucker, Margaret A, Morton, Lindsay M

“…Previous studies have reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of developing cutaneous melanoma; however, risks associated…”
Get full text

Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: Estimations based on SEER‐Medicare‐linked data resource by Lam, Clara, Cronin, Kathleen, Ballard, Rachel, Mariotto, Angela

“…Diabetes prevalence and racial health disparities in the diabetic population are increasing in the US. Population‐based cancer‐specific survival estimates for…”
Get full text

Utilization of the Cancer Medications Enquiry Database (CanMED)-National Drug Codes (NDC): Assessment of Systemic Breast Cancer Treatment Patterns by Rivera, Donna R, Grothen, Andrew, Ohm, Bradley, McNeel, Timothy S, Brennan, Sean, Lam, Clara J K, Penberthy, Lynne, Enewold, Lindsey, Petkov, Valentina I

“…Abstract Cancer Medications Enquiry Database (CanMED) is comprised of two interactive, nomenclature-specific databases within the Observational Research in…”
Get full text

Estimating Chemotherapy Use Among Patients With a Prior Primary Cancer Diagnosis Using SEER-Medicare Data by Lam, Clara J K, Enewold, Lindsey, McNeel, Timothy S, White, Dolly P, Warren, Joan L, Mariotto, Angela B

“…Abstract Cancer treatment studies commonly exclude patients with prior primary cancers due to difficulties in ascertaining for which site treatment is…”
Get full text

Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries by Lam, Clara J K, Warren, Joan L, Nielsen, Matthew, Smith, Angela, Boyd, Eric, Barrett, Michael J, Mariotto, Angela B

“…Abstract The growing use of oral systemic therapies and transition of some cancer treatments to the outpatient setting makes capturing all cancer case patients…”
Get full text

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients by Rivera, Donna R, Enewold, Lindsey, Barrett, Michael J, Banegas, Matthew P, Filipski, Kelly K, Freedman, Andrew N, Lam, Clara K, Mariotto, Angela

“…Following approval of imatinib, a breakthrough tyrosine kinase inhibitor (TKI), survival significantly improved by more than 20% since 2001 among treated…”
Get full text

Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer by Lam, Clara, Diessner, Brandon, Andrade, Katherine, Stackland, Sydnie, Park, Leah, Mehta, Sandhya, Lin, Feng, Kwong, Winghan Jackie

“…The objectives were to investigate the differences in per patient per month (PPPM) healthcare resource utilization (HCRU) and costs among commercially insured…”
Get full text

Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries by Noone, Anne-Michelle, Lam, Clara J K, Smith, Angela B, Nielsen, Matthew E, Boyd, Eric, Mariotto, Angela B, Banerjee, Mousumi

“…Population-based cancer incidence rates of bladder cancer may be underestimated. Accurate estimates are needed for understanding the burden of bladder cancer…”
Get more information

Development and Utility of the Observational Research in Oncology Toolbox: Cancer Medications Enquiry Database-Healthcare Common Procedure Coding System (HCPCS) by Rivera, Donna R, Lam, Clara J K, Enewold, Lindsey, Petkov, Valentina I, Tran, Quyen, Brennan, Sean, Dickie, Lois, McNeel, Timothy S, Noone, Annie M, Ohm, Bradley, White, Dolly P, Warren, Joan L, Mariotto, Angela B, Penberthy, Lynne

“…Abstract Purpose Health-care claims are of increasing utility as a rich, real-world data resource for conducting treatment-related cancer research. However,…”
Get full text

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA by Barzi, Afsaneh, Lin, Feng, Song, Jinlin, Lam, Clara, Nie, Xiaoyu, Noman, Ahmed, Kwong, Winghan J.

“…Background Trastuzumab in combination with chemotherapy is the standard first-line (1L) treatment for HER2+ metastatic gastric cancer (mGC) in the USA…”
Get full text

Melanoma Tumor Depth Quality Audit: A Nonmatch Analysis by Sanchez, Pamela, Adamo, Margaret Peggy, Lam, Clara J K, Steven, Jennifer, Brest, Ariel, Negoita, Serban

“…The National Cancer Institute's Surveillance Research Program (SRP) received reports from cancer registries in the Surveillance, Epidemiology, and End Results…”
Get full text

Provider Engagement in Radiation Oncology Data Science: Workshop Report by Jain, Anshu K, Aneja, Sanjay, Fuller, Clifton D, Dicker, Adam P, Chung, Caroline, Kim, Erika, Kirby, Justin S, Quon, Harry, Lam, Clara J K, Louv, William C, Ahern, Chris, Xiao, Ying, McNutt, Todd R, Housri, Nadine, Ennis, Ronald D, Kang, John, Tang, Ying, Higley, Howard, Berny-Lang, Michelle A, Camphausen, Kevin A

Get more information

Testing patterns and prevalence of PIK3CA , AKT1 , and PTEN alterations among patients (pts) with HR+/HER2- metastatic breast cancer (mBC) in the US by Park, Leah, Thompson, Samantha L, Roose, James, Lu, Yichen, Chaki, Moumita, Lam, Clara, Iorgulescu, Bryan

“…1041 Background: Biomarkers play an essential role to inform treatment decisions in mBC. In hormone receptor positive/HER2 negative (HR+/HER2-) mBC,…”
Get full text

Treatment patterns and clinical outcomes following endocrine resistance among with HER2-low metastatic breast cancer: Retrospective observational study by Mehta, Sandhya, Savill, Kristin M. Zimmerman, Wang, Peng, Pathak, Prathamesh, Lam, Clara, Kwong, Jackie, Feinberg, Bruce A.

“…e13069 Background: Endocrine therapy (ET) ± CDK 4/6 inhibitors is a common initial treatment for HR+/HER2-low (IHC 1+ or IHC2+/ISH-) metastatic breast cancer…”
Get full text